ChiCTR2600118178 版本V1.0 版本创建时间2026/02/03 09:19:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118178 

最近更新日期:

Date of Last Refreshed on:

2026-02-03 09:19:10 

注册时间:

Date of Registration:

2026-02-03 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

胸肺物理治疗在预防机械通气患者呼吸机相关肺炎中的效果研究

Public title:

Effect of chest physiotherapy on the prevention of VAP in patients with mechanical nentilation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胸肺物理治疗在预防机械通气患者呼吸机相关肺炎中的效果研究

Scientific title:

Effect of chest physiotherapy on the prevention of VAP in patients with mechanical nentilation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

罗政 

研究负责人:

罗政 

Applicant:

Zheng Luo 

Study leader:

Zheng Luo 

申请注册联系人电话:

Applicant telephone:

+86 158 1108 5109

研究负责人电话:

Study leader's
telephone:

+86 158 1108 5109

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lz342953920@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

lz342953920@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区复兴路28号301医院第二医学中心呼吸与危重症医学科

研究负责人通讯地址:

北京市海淀区复兴路28号301医院第二医学中心呼吸与危重症医学科

Applicant address:

Department of Respiratory and Critical Care Medicine, the Second Medical Center, PLA Hospital

Study leader's address:

Department of Respiratory and Critical Care Medicine, the Second Medical Center, PLA Hospital

申请注册联系人邮政编码:

Applicant postcode:

100853

研究负责人邮政编码:

Study leader's postcode:

100853

申请人所在单位:

解放军总医院医院第二医学中心呼吸与危重症医学科

Applicant's institution:

Department of Respiratory and Critical Care Medicine, the Second Medical Center, PLA Hospital

研究负责人所在单位:

解放军总医院医院第二医学中心呼吸与危重症医学科

Affiliation of the Leader:

Department of Respiratory and Critical Care Medicine, the Second Medical Center, PLA Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

S2024-606-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军总医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the General Hospital of the PLA Hostipal

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-31 00:00:00

伦理委员会联系人:

曹江

Contact Name of the ethic committee:

caojiang

伦理委员会联系地址:

北京市海淀区复兴路28号

Contact Address of the ethic committee:

No. 28, Fuxing Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 158 1108 5109

伦理委员会联系人邮箱:

Contact email of the ethic committee:

lz342953920@foxmail.com

研究实施负责(组长)单位:

解放军总医院第二医学中心

Primary sponsor:

the Second Medical Center, PLA Hospital

研究实施负责(组长)单位地址:

北京市复兴路28号

Primary sponsor's address:

No. 28, Fuxing Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

beijing

City:

单位(医院):

解放军总医院第二医学中心

具体地址:

北京市海淀区复兴路28号

Institution
hospital:

the Second Medical Center, PLA Hospital

Address:

No. 28, Fuxing Road, Haidian District, Beijing

经费或物资来源:

医院科研课题

Source(s) of funding:

Hospital scientific research projects

研究疾病:

无  

Target disease:

None

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟通过循证护理方法构建ICU机械通气患者胸部物理治疗方案,观察胸部物理治疗方案对机械通气时间、VAP发生率以及外周血CD4+T细胞亚群和免疫相关生物标记物的变化,为ICU机械通气患者VAP的预防/治疗策略提供有价值的理论根据。  

Objectives of Study:

This study intends to construct a chest physical therapy plan for ICU patients with mechanical ventilation through evidence-based nursing methods, observe the changes of the chest physical therapy plan on the duration of mechanical ventilation, the incidence of VAP, peripheral blood CD4+T cell subsets and immune-related biomarkers, and provide valuable theoretical basis for the prevention/treatment strategies of VAP in ICU patients with mechanical ventilation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

选择第一医学中心外科ICU以及肝胆外科ICU进行机械通气的患者为研究对象。 1.年龄>18岁; 2.首次气管插管行机械通气患者; 3.机械通气>=24h; 4.心血管系统稳定:心率60-120次/min;收缩压90-180mmHg(1mmHg=0.133kPa);使用小剂量血管活性药物支持,多巴胺<=10mg/(kg·min)或去甲肾上腺素/肾上腺素<=0.1 mg/(kg·min);无心律失常及缺血性胸痛。 5.呼吸系统稳定:呼吸频率<25次/min;SpO2>=90%;机械通气时吸入氧浓度(FiO2)<60%、 呼末正压(PEEP)<=10cmH2O;气管插管妥善固定。

Inclusion criteria

Patients who received mechanical ventilation in the surgical ICU and hepatobiliary surgery ICU of the First Medical Center were selected as the research subjects. Inclusion criteria 1. Age > 18 years old; 2. Patients who underwent mechanical ventilation with tracheal intubation for the first time; 3. Mechanical ventilation >=24 hours; 4. Stable cardiovascular system: Heart rate 60-120 beats per minute; Systolic blood pressure: 90-180 MMHG (1mmHg=0.133kPa); Support with low-dose vasoactive drugs, with dopamine <=10mg/ (kg·min) or norepinephrine/epinephrine <=0.1 mg/ (kg·min); There was no arrhythmia or ischemic chest pain. 5. Stable respiratory system: Respiratory rate < 25 breaths per minute; SpO2>=90%; During mechanical ventilation, the inhaled oxygen concentration (FiO2) was less than 60% and the positive end-expiratory pressure (PEEP) was less than or equal to 10cmH2O. The tracheal intubation was properly fixed.

排除标准:

1.患有神经肌肉疾病需机械通气维持呼吸,急性脑卒中、脊柱损伤、疑似或证实患有肌源性疾病或神经源性肌力减退; 2.精神类疾病发作或存在视听障碍,不能配合; 3.全身大面积创伤、呼吸心跳骤停患者; 4.临终或需立即转院治疗; 5.中枢系统疾病导致的呼吸功能衰竭; 6.其他原因无法进行胸部物理治疗的患者。

Exclusion criteria:

1.Patients with neuromuscular diseases requiring mechanical ventilation to maintain breathing, acute stroke, spinal cord injury, suspected or confirmed myogenic diseases or neurogenic muscle weakness; 2. Onset of mental illness or presence of audio-visual impairment, unable to cooperate; 3. Patients with extensive trauma all over the body and cardiac arrest; 4. Terminally ill or requiring immediate transfer to another hospital for treatment; 5. Respiratory failure caused by central nervous system diseases; 6. Patients who are unable to undergo chest physical therapy for other reasons.

研究实施时间:

Study execute time:

From 2023-01-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-10 00:00:00 To 2024-12-19 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

34

Group:

Control group

Sample size:

干预措施:

对照组给予常规护理,所有医护工作均需遵循医疗卫生机构消毒、灭菌和医院感染控制相关的基本要求和原则,保障医疗器具消毒灭菌,严格无菌操作,合理应用抗菌药物等。

干预措施代码:

1

Intervention:

The control group was given routine care. All medical and nursing work must follow the basic requirements and principles related to disinfection, sterilization and hospital infection control in medical and health institutions, ensure the disinfection and sterilization of medical equipment, strictly perform aseptic operations, and rationally apply antibacterial drugs, etc.

Intervention code:

组别:

干预组

样本量:

34

Group:

Intervention group

Sample size:

干预措施:

干预组在对照组实施护理措施的基础上,由获得解放军总医院胸部物理治疗师证书的护理人员按照ICU机械通气患者胸部物理治疗方案实施,干预至患者转出ICU或出院时终止。

干预措施代码:

2

Intervention:

On the basis of implementing nursing measures in the control group, the intervention group was carried out by nursing staff who obtained the certificate of thoracic physical therapist from the General Hospital of the People's Liberation Army in accordance with the thoracic physical therapy plan for patients with mechanical ventilation in the ICU. The intervention was terminated when the patients were transferred out of the ICU or discharged.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

beijing

City:

单位(医院):

解放军总医院第二医学中心 

单位级别:

三甲 

Institution
hospital:

the Second Medical Center, PLA Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

VAP发生率

指标类型:

主要指标

Outcome:

Incidence of VAP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

机械通气时间(h)

指标类型:

主要指标

Outcome:

Mechanical ventilation time (h)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺顺应性

指标类型:

次要指标

Outcome:

cst

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

外周血液中CD4+T细胞亚群(Th17、Treg)及细胞因子(IL-6、IL-10、IL-17 、STAT3、Foxp3、RORγt)。

指标类型:

次要指标

Outcome:

CD4+T cell subsets (Th17, Treg) and cytokines (IL-6, IL-10, IL-17, STAT3, Foxp3, RORγt) in peripheral blood.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

痰液中MUC5AC、SP-D蛋白

指标类型:

次要指标

Outcome:

MUC5AC and SP-D proteins in sputum.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

痰液

组织:

Sample Name:

Sputum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机分组方法,根据随机数字表生产的随机码,将研究对象以机械通气的先后顺序分为实验组和对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

By using the random grouping method, according to the random codes produced by the random number table, the research subjects were divided into the experimental group and the control group in the order of mechanical ventilation.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲,研究对象不知晓组别及干预方案

Blinding:

This study adopted a single-blind approach. Subjects are unaware of their group assignment and the intervention protocol.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025.12.31 国家生物信息中心 China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2025.12.31 China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-03 09:19:10